ATE169302T1 - Phosphono suphonate verbindungen zur behandlung abnormalen kalzium- und phospat- metabolismuses - Google Patents

Phosphono suphonate verbindungen zur behandlung abnormalen kalzium- und phospat- metabolismuses

Info

Publication number
ATE169302T1
ATE169302T1 AT93914150T AT93914150T ATE169302T1 AT E169302 T1 ATE169302 T1 AT E169302T1 AT 93914150 T AT93914150 T AT 93914150T AT 93914150 T AT93914150 T AT 93914150T AT E169302 T1 ATE169302 T1 AT E169302T1
Authority
AT
Austria
Prior art keywords
present
treatment
metabolism
suphonate
phospate
Prior art date
Application number
AT93914150T
Other languages
English (en)
Inventor
Susan Mary Dansereau
Frank Hallock Ebetino
Allan Vincent Bayless
Original Assignee
Procter & Gamble Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/055,809 external-priority patent/US5731299A/en
Application filed by Procter & Gamble Pharma filed Critical Procter & Gamble Pharma
Application granted granted Critical
Publication of ATE169302T1 publication Critical patent/ATE169302T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808Acyclic saturated acids which can have further substituents on alkyl
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/5532Seven-(or more) membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576Six-membered rings
    • C07F9/5765Six-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576Six-membered rings
    • C07F9/58Pyridine rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576Six-membered rings
    • C07F9/59Hydrogenated pyridine rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503Five-membered rings
    • C07F9/6506Five-membered rings having the nitrogen atoms in positions 1 and 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509Six-membered rings
    • C07F9/6512Six-membered rings having the nitrogen atoms in positions 1 and 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Removal Of Specific Substances (AREA)
AT93914150T 1992-05-29 1993-05-26 Phosphono suphonate verbindungen zur behandlung abnormalen kalzium- und phospat- metabolismuses ATE169302T1 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US89088592A 1992-05-29 1992-05-29
US89148792A 1992-05-29 1992-05-29
US89135592A 1992-05-29 1992-05-29
US89149092A 1992-05-29 1992-05-29
US89088692A 1992-05-29 1992-05-29
US89130992A 1992-05-29 1992-05-29
US08/055,809 US5731299A (en) 1992-05-29 1993-05-07 Phosphonosulfonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism

Publications (1)

Publication Number Publication Date
ATE169302T1 true ATE169302T1 (de) 1998-08-15

Family

ID=27568101

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93914150T ATE169302T1 (de) 1992-05-29 1993-05-26 Phosphono suphonate verbindungen zur behandlung abnormalen kalzium- und phospat- metabolismuses

Country Status (19)

Country Link
EP (1) EP0642518B1 (de)
JP (1) JP3781769B2 (de)
CN (3) CN1087640A (de)
AT (1) ATE169302T1 (de)
AU (1) AU659565B2 (de)
CA (1) CA2136823C (de)
CZ (1) CZ295894A3 (de)
DE (1) DE69320187T2 (de)
DK (1) DK0642518T3 (de)
ES (1) ES2123057T3 (de)
FI (1) FI945592A0 (de)
HU (1) HUT71907A (de)
IL (1) IL105839A (de)
MX (1) MX9303242A (de)
NO (1) NO305958B1 (de)
NZ (1) NZ253523A (de)
SG (1) SG90009A1 (de)
SK (1) SK145594A3 (de)
WO (1) WO1993024495A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731299A (en) * 1992-05-29 1998-03-24 The Procter & Gamble Company Phosphonosulfonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism
US5712396A (en) * 1992-10-28 1998-01-27 Magnin; David R. α-phosphonosulfonate squalene synthetase inhibitors
CA2107644A1 (en) * 1992-10-28 1994-04-29 David R. Magnin .alpha.-phosphonosulfonae squalene synthetase inhibitors and methd
US5447922A (en) * 1994-08-24 1995-09-05 Bristol-Myers Squibb Company α-phosphonosulfinic squalene synthetase inhibitors
US5618964A (en) * 1995-06-07 1997-04-08 Bristol-Myers Squibb Company Prodrug esters of phosphonosulfonate squalene synthetase inhibitors and method
CN106883165B (zh) * 2017-01-03 2019-03-26 中节能万润股份有限公司 一种模板剂中间体的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT352142B (de) * 1977-03-29 1979-09-10 Benckiser Knapsack Gmbh Verfahren zur herstellung von neuen n- sulfoalkan-aminoalkanphosphonsaeuren und deren alkalisalzen
DE3434667A1 (de) * 1984-09-21 1986-04-03 Henkel KGaA, 4000 Düsseldorf 4-dimethylamino-1-hydroxybutan-1,1-diphosphonsaeure, deren wasserloesliche salze, verfahren zu ihrer herstellung sowie ihre verwendung
IL77243A (en) * 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
IL86951A (en) * 1987-07-06 1996-07-23 Procter & Gamble Pharma Methylene phosphonoalkylphosphinates and pharmaceutical preparations containing them
IL86095A0 (de) * 1987-09-30 1988-09-30 Lilly Co Eli
JPH02184693A (ja) * 1989-01-03 1990-07-19 Gas Res Inst 弗素化ホスホンスルホン酸及びその製法
US5731299A (en) * 1992-05-29 1998-03-24 The Procter & Gamble Company Phosphonosulfonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism

Also Published As

Publication number Publication date
CA2136823C (en) 1998-05-26
EP0642518A1 (de) 1995-03-15
NO944498D0 (no) 1994-11-24
IL105839A0 (en) 1993-09-22
ES2123057T3 (es) 1999-01-01
CN1087640A (zh) 1994-06-08
NO305958B1 (no) 1999-08-23
EP0642518B1 (de) 1998-08-05
AU659565B2 (en) 1995-05-18
MX9303242A (es) 1994-05-31
FI945592A (fi) 1994-11-28
JP3781769B2 (ja) 2006-05-31
CA2136823A1 (en) 1993-12-09
CZ295894A3 (en) 1995-10-18
HUT71907A (en) 1996-02-28
NZ253523A (en) 1997-01-29
HU9403411D0 (en) 1995-02-28
CN1255501A (zh) 2000-06-07
DK0642518T3 (da) 1998-12-14
FI945592A0 (fi) 1994-11-28
SK145594A3 (en) 1995-07-11
IL105839A (en) 2001-08-26
WO1993024495A1 (en) 1993-12-09
JPH07507314A (ja) 1995-08-10
SG90009A1 (en) 2002-07-23
AU4391693A (en) 1993-12-30
CN1229083A (zh) 1999-09-22
DE69320187T2 (de) 1999-02-11
DE69320187D1 (de) 1998-09-10
NO944498L (no) 1995-01-26

Similar Documents

Publication Publication Date Title
ATE203409T1 (de) Phosphonocarboxylat-verbindungen zur behandlung abnormalen calzium- und phosphat-metabolismus
RU94046137A (ru) Фосфонсульфонатные соединения для лечения аномального кальциевого и фосфатного обмена, фармацевтическая композиция
RU94046146A (ru) Тиозамещенные азотсодержащие гетероциклические фосфонатные соединения, фармкомпозиция и способ лечения
ATE169302T1 (de) Phosphono suphonate verbindungen zur behandlung abnormalen kalzium- und phospat- metabolismuses
RU94046106A (ru) Содержащие четвертичный азот фосфонатные соединения для лечения анормального кальциевого и фосфатного метаболизма, а также профилактики и лечения зубных налетов и зубных камней, фармацевтические композиции, способ лечения
CA2188066A1 (en) Thio-Substituted Phosphonate Compounds
DE69327240T2 (de) Quaternäre stickstoff-enthaltende phosphonat-verbindungen zur behandlung abnormalen calzium-und phosphat-metabolismus
CA2136822A1 (en) Thio-Substituted Cyclic Phosphonate Compounds for Treating Abnormal Calcium and Phosphate Metabolism
RU94046103A (ru) Содержащие четвертичный азот фосфонатные соединения для лечения аномального кальциевого и фосфатного метаболизма, фармацевтическая композиция, способ лечения
RU94046139A (ru) Содержащие четвертичный азот фосфанатные соединения для лечения аномального кальциевого и фосфатного метаболизма, фармацевтическая композиция
RU94046138A (ru) Тиозамещенные циклические фосфонатные соединения для лечения аномального кальциевого и фосфатного метаболизма, фармацевтическая композиция, способ лечения

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee